DYSAUTONOMIA CONFERENCE 2020
Review of Presentations
The following list provides commentary on selected presentations from the Dysautonomia International virtual 2020 conference. I plan to add reviews of the "pending" presentations as they become available for viewing. I do not plan to watch 100 % of the presentations; the conference was quite lengthy.
These talks will be temporarily available for viewing online, as of 11-30-20. See this blog post for an introduction.
It is essential to first have a basic understanding of dysautonomia and the autonomic nervous system in order to understand the content on this page.
Please start by reviewing this blog post and introductory webpage in order to learn what dysautonomia is and why it is so important to Sjogren’s patients.
My comments reflect my interpretation of the oral presentation. I did my best to relay what the presenter intended to say. I cannot verify the accuracy of the content. Please discuss any questions you may have about your conditions and any treatments with your neurologist, PCP, or other clinician providing care.
It is too big a task to provide links to information on every topic discussed, or even to define terms and common abbreviations. Please use a search engine as needed and refer the Dysautonomia International website.
Autonomic disorders by B. Grubb
GI dysmotility by Laura Pace
Autonomic regulation of immune system by K. Tracey
Pain Management by P. Chopra
Exercise Therapy by N. Miranda
POTs/OI Workup by B. Goodman
Day 1: October 15, 2020
Overview of Autonomic Disorders, Blair Grubb, MD
Autonomic nervous system (ANS): Good intro to what the ANS does, how it is structured.
The ANS keeps the body regulated by controlling the automatic functions of the body such as heart rate, blood pressure, breathing, digestion, temperature control, sweating, bowel and bladder function, erectile function. etc.
Our view of the ANS as being distinctly divided into the sympathetic and parasympathetic nervous systems is oversimplified. It still can be helpful to understand this simplistic view as a starting point.
Sympathetic nervous system: fight or flight, with norepinephrine as a dominant neurotransmitter.
Parasympathetic nervous system: rest and digest, with acetylcholine as dominant neurotransmitter.
But the ANS is not a simple 2-track system.
There are other neurotransmitters involved, such as nitrous oxide. Nice diagrams in his talk show how neurotransmitters work to carry electrical signals across nerves. The same nerve fiber can have both sympathetic and parasympathetic activity and transmitters
Nerves help regulate the immune system and inflammation, and vice versa (see Keynote by Kevin Tracey, MD, described below).
Dr. Grubb reviews orthostatic intolerance (OI) including POTs and POTS variants, pure autonomic failure, and multiple system atrophy. He talks about who gets these and common underlying diseases/triggers. He does not go into management, which is covered in later talks.
These conditions are also covered in detail by Dr. Novak. They are both good talks.
"Gems" from this talk:
1. Keep in mind that POTs criteria (see Novak), like all classification criteria, are arbitrary. (My note: this is true of Sjogren's classification criteria too!) POTS criteria will probably change over time as we gain a better understanding of this condition and discover biomarkers that reflect the entire syndrome, not just the HR and BP changes.
2. He goes into a fascinating discussion of autoimmune vs. autoinflammatory diseases, and how some so-called autoimmune diseases may be autoinflammatory or have an autoinflammatory component. His current thinking is that POTS is an autoinflammatory disease.
My comment: POTS and Sjogren's may have a common underlying autoinflammation which drives both diseases. Many non-rheumatology doctors are not familiar with these concepts.
3. The head up tilt table test was created in the late 1980s to help define POTS and other OI conditions. It remains the most standardized test, but is not always available. A careful standing test for HR and BP that yields positive results is probably adequate for POTS diagnosis; symptomatic patients who don't make the cutoff my need referral for a tilt table tests. Involuntary muscle contractions during the standing tests may skew the results.
Overview of Orthostatic Intolerance (OI), Peter Novak, MD
OI, in short, means you feel awful upright, especially standing, due to abnormal control of heart rate (hr) and blood pressure (bp). There are many versions of OI, with POTs being the most common. If you have dysautonomia symptoms that do not meet the classic POTS criteria, Dr. Novak suggests that you seek evaluation at a dysautonomia specialty clinic to determine the diagnosis.
POTS (postural orthostatic tachycardia syndrome) is defined by heart rate (hr) increase of 30 beats per minute (bpm) with 10 min. tilt table or standing test, 40 bpm if under age 19. Blood pressure (bp) is usually maintained. Note that later lecturers admitted that strict 30 bpm cutoff may not be appropriate in all cases.
BP occasionally falls with POTS, but usually not to the point of syncope (fainting). Fainting usually occurs when cerebral (brain) blood flow drops 40 % or more
POTS differs from inappropriate sinus tachycardia, which exhibits high heart rate in all positions, including supine.
Hyperadrenergic POTS occurs when bp goes up w/ the tachycardia.
A condition called HCH, or hypocapneic cerebral hypoperfusion, occurs with low blood carbon dioxide levels in the blood. It is sometimes called “POTS without the tachycardia.” It is treated the same way.
Comments about POTS treatment: Unlike a few other experts, Dr. Novak recommended avoiding beta blockers for POTS unless elevated bp.
He did state that midodrine, fludrocortisone (Florinef), and pyridostigmine (Mestinon) were all helpful POTS medications.
OCHOS is orthostatic cerebral hypoperfusion syndrome which may be caused by small blood vessel disease, rather than dysautonomia. People with this often have trouble with fainting.
Overview of postural tachycardia syndrome, Satish Raj, MD, MSCI
Recommend if you have symptoms
I recommend the pharmacological management talk by the same author on day 4, below. He went over a lot of the same treatment information in both talks.
POTS is not just elevated heart rate with upright posture; it is a multisystem condition causing profound disability in many. POTS is the final common pathway of many genetic and acquired autonomic conditions. It often occurs post viral, post trauma, in EDS (Ehlers Danlos Syndrome), ME/ CFS (chronic fatigue syndrome) and in autoimmune disease (especially Sjogren's which was mentioned by nearly every other lecturer but not Dr. Raj).
Note that POTS can be managed enough to improve function. At this time there is no cure. POTS is not defined as POTS until at least 3-6 months of symptoms. People can have a post viral syndrome that looks like POTS but clears in a few weeks or months. That is not POTS.
He divides into cardiac features and non cardiac. Both sets of features are mostly worse on upright posture. These categories can be a in the gray area. For example, brain fog can be impacted by lack of blood flow to the brain.
CARDIAC: elevated heart rate (hr), shortness of breath, chest discomfort, light headedness. He did not mention heart palpitations which many others did.
NON-CARDIAC: mental changes / brain fog, headache, often severe > 90 %, tremulous, fatigue, sleep complaints
He covers in great detail normal hr elevation and adjustment with standing.. With POTS, you don't adjust hr back down but keep going up. Patients rarely faint but often feel like it. Much of this is due to blood pooling in legs and abdomen caused by inadequate "tightening" of veins in the lower half of the body. That is how the body adapts to posture changes to keep blood flowing up. (Thus the compression garment recommendations).
> 95 % female, onset often puberty teens, but can happen later. Gender bias is is one reason the condition is often blamed on psychological problems, or "functional neurologic disorder."
POTS IS NOT PSYCHOLOGICAL in origin! POTS patients have the same rates of mental health conditions such as anxiety, depression or panic disorder as the general population. But patients are often labeled as having a psychiatric disorder, and not diagnosed and given the medical treatment they need.
Dr. Raj reviews evaluation, as do most lecturers. Dr. Goodman's lecture (Day 4) proposes a slightly different set of tests.
Both suggest autonomic reflex testing, and the obvious : History, physical, exam, orthostatic vital signs (10 minutes), CBC, metabolic panel. Dr Raj's unique recs (these are not done that often): Blood volume assessment via nuclear medicine scan, echocardiogram to be sure heart is structurally normal (r/o cardiomyopathy), and exercise capacity assessment.
Many POTS patients have a revved up sympathetic nervous system, even if it is enough to cause high blood pressure. The three categories, hyperadrenergic POTS, neuropathic POTs and hypovolemic POTS have a lot of overlap and are not actually all that distinct. Many patients have features of 2 or 3 of these versions of POTS. He goes into some detail on this, but the main point was to avoid meds that increase norepinephrine such as SNRIs in all versions.
See his lecture on treatment (Day 4) for details about treatments, as well as other lectures by other experts who cover POTS treatments.
He discussed exercise and the Levine protocol, emphasizing the importance of exercise as part of the treatment. Exercise not just increases fitness, but also increases blood volume, and the ability of the heart to pump blood. It helps neutralize sympathetic nerve overactivity.
POTS patients who exercise improve orthostatic tachycardia and have improved quality of life You must exercise regularly, at least four days a week. In general, you do not start with upright exercise (aerobic is needed but many don't tolerate upright early in the program). Recs include swimming, recumbent bike, and rowing. These may be hard to access during the pandemic, but there are other options to start with as discussed in Nicole Miranda's excellent presentation.
My NOTE about Exercise programs: I disagree on the approach of making it worse before getting better which the Levine protocol patients usually experience.
Please watch Nicole Miranda's fantastic lecture on exercise and POTs, day 3. It is also excellent for Sjogren's patients who experience setbacks from even brief exercise. She shows you how to do this without backfiring. On a personal note: I had severe POTS (now moderate) when I started an exercise program based on Dr. Levine's protocol. I intuited that I needed to go much more slowly than his program suggested. It took 3-4 months to build up the exercise up to a level where it made a difference. It can be done, but patients need support and guidance, and a willingness to persevere and learn through trial and error.
Gastrointestinal Dysmotility in Autonomic Disorders, Laura Pace, MD, PhD
Recommend, especially if you have been told you have "irritible bowel syndrome."
Dr. Pace covers a lot of material about GI dysfunction, focusing mostly, but not entirely, on motility problems.
Great simple explanation of GI system organs and what they do. She also mentions the "enteric nervous system" where the autonomic nervous system (ANS) interacts with immune cells, especially mast cells. Known cross talk: the immune cells impact the nerve cells and vice versa.
She mentions the importance of the gut microbiome in training the immune system, although there are many unknowns about how this works.
Because GI motility issues are usually dysautonomias, Dr. Pace reviews the various motility tests that are used for esophagus, stomach and intestines. I learned a lot of things I only had a vague idea of, including how the Smart pill wireless capsule works.
Note that these tests measure motility problems but not the cause behind them.
VERY HIGH rates of GI dysmotility seen in dysautonomia patients, about 90%.
Most with motility problems in one area of the GI tract such as the stomach, will also have dysmotility in another part such as small intestine, colon, or esophagus.
Goes into some detail about how to precisely determine non-classic (not IgE mediated) food allergies using confocal laser endoscopy.
No blanket recommendations about diet (obviously avoid allergens) other than limit processed foods which break down the mucosal barrier. Note that she did not mention gluten or dairy as foods to be avoided unless specific issue with them.
Chronic nausea often more related to small intestine transit delay rather than how problematic GI emptying is(gastroparesis). Difficult to treat, but new drugs are being tried (did not give specifics).
"Irritable bowel syndrome" (IBS), functional neurologic disorders, and other labels are often used to avoid evaluation of complex neurologic problems that neurologists, gastroenterologists, and most clinicians remain unfamiliar with.
IBS probably has these causes: dysautonomia/ motility issues, non classic food allergy, and dysbiosis (abnormal microbiome). This often requires special testing for diagnosis. Patients diagnosed with IBS should request further evaluation.
Dr. Pace and other presenters repeatedly talked about the problem of physicians taking ownership of complex disorders, especially female-dominated conditions. These tend to be treated dismissively and psychologized, resulting in inadequate medical care.
There must be systemic change to provide adequate care of complex diseases like dysautonomias (and Sjogren's! my comment). This requires better research, collaboration between specialty areas and addressing the patient as a whole, not as a person with a scattered collection of symptoms. Often, the symptoms are very much connected!
Day 2: October 16, 2020
Small Fiber Neuropathies (SFNs), Kamal Chemali, MD
There is no consensus definition for SFN, other than it involves damage or die-off of the small unmyelinated and thinly myelinated nerve fibers in the peripheral nervous system.
80- 90 % of the autonomic nervous system (ANS) is innervated by these small fibers.
SFNs impacting sensations such as pain, light touch, temperature, and gut sensations often occur together with dysautonomia.
Full autonomic testing:
QSART (sweating function)
Cardiovagal (hr variability on deep breathing)
Valsalva (hr, bp changes with bearing down, in this example, breathing against a tube)
Tilt table test
These tests support but do not rule out dysautonomia and SFN:
Skin biopsy positive in 50 %
QSART positive in 50 %
Together, skin bx and QSART pick up 75 % dysautonamias
Negative skin biopsy does not r/o SFN, but helps if positive. The gold standard for diagnosis is clinical judgement.
Causes: There are many causes of SFN: diabetes, prediabetes ( these are the most common), autoimmunity esp. Sjogren’s, elevated triglycerides, high cholesterol, B12 deficiency, too much B6, alcohol, toxins, HIV and post viral.
Sjogren’s is #1 autoimmune disease associated with dysautonomia and SFN. Others mentioned: SLE, amyloidosis, RA, systemic sclerosis. 11-13 % of POTs patients have Hashimotos. Celiac disease also associated with POTS.
Dr. Chemali Considers fibromylagia as part of the SFN/ dysautonomia spectrum. This coincides with Dr. Oaklander’s and Farhad's work at Harvard. This view is not shared among all neurologists.
Autoimmune Dysautonomias, Kamal Chemali, MD
These are very common, very underdiagnosed. Seen in many AI rheumatic diseases; often subclinical but measurable. TBD: Does it lower quality of life, and if so how much?
Sjogren’s was a recurrent theme in this conference:
60 % of Sjogren’s patients develop SFN
50 % have ANS dysfunction symptoms
66 % have abnormal autonomic testing, even in the absence of symptoms! We don't know if mild and subclinical cases will progress to clinically significant problems.
Dr Chemali, a neurologist, provided an inaccurate explanation of how Sjogrens is diagnosed, but points for trying!
Many dysautonomia specialists are learning to be on the lookout for Sjogren’s, because they may first present with neurologic features, especially SFN/ dysautonomia.
Cardiovascular dysautonomias in AI rheumatic diseases do not correlate with organ system involvement. Testing for ANS dysfunction routinely can detect it early.
Sex Hormones and Dysautonomia, Svetlana Blitshteyn, MD
Lengthy review of menstrual cycle, and hormonal changes.
Women tend to have first onset of dysautonomia symptoms with menarche (first period) and worsened symptoms during periods, menopause. Some reproductive age women do better with hormonal contraceptives (assuming they are otherwise appropriate).
I could not figure out a practical take home message other than women are more prone to dysautonomia, possibly due to the interaction of sex hormones with inflammatory pathways.
Autonomic regulation of glucose, Cyndya Shibao, MD
Dr. Shibao presents some fascinating new data showing that POTS patients are prone to abnormalities in glucose metabolism. She discusses sympathetic nervous system (SNS) overactivity, and how this impacts glucose metabolism. The SNS is overactive in POTS patients and in many with autoimmune rheumatic diseases.
POTS patients often have abnormal glucose tolerance tests even if their fasting blood glucose is normal. Hemoglobin A1c is a better test to screen for prediabetes in the dysautonomia population. They are at increased risk of type 2 diabetes even at normal weights.
She goes into some detail about why POTS patients feel better on low carbohydrate diets, and why they often feel worse after eating. They often respond to eating with increased GI symptoms and elevated heart rates.
This is why small frequent meals are key.
The lecture is a bit hard to follow. She does not define medical terms such as "postprandial" (this means after meals). It took me a while to catch on to why she was using obese non-diabetic patients as controls for normal BMI POTS patients. I did figure that out, and she explained her reasoning during the Q and A at the end.
This is fascinating, cutting edge research, but do be prepared for a dense lecture.
She does provide a good review of glucose metabolism and how diabetes develops. We still have a lot to learn about this topic in autoimmune and dysautonomia patients.
Day 3: October 17, 2020
Keynote: Autonomic regulation of the immune system, Kevin Tracey, MD
Highly Recommend, even if you don’t have dysautonomia
Wow! There may actually be hope for non-drug treatments for autoimmune diseases. Vagus nerve stimulation (implants) have demonstrated exciting early results for rheumatoid arthritis and Crohn's disease. Dr. Tracey studies surgical implants. This is still in the research phase. While Sjogren's has not been tested, Dr. Wan-Fai Ng in the UK is studying external vagus nerve stimulation for Sjogren's fatigue. (my comment re Dr. Ng).
Dr. Tracey explains the relationship between the nervous system and inflammation. He shows how electrical stimulation of the vagus nerve changes chemical signals that create inflammation. Even if you don't want to watch the fascinating science behind this, I highly recommend the Q and A at the end.
Pain Management in Dysautonomia, Pradeep Chopra, MD
Dr. Chopra covered a huge range of topics. Some highlights:
Structural pain- caused by inflammation
Neuropathic pain- caused by nerve inflammation, can arise from structural damage
Small Fiber neuropathy (SFN) is caused by damage to the smallest nerves. Changes to temperature, touch, creepy crawly feeling, tingling
Autonomic neuropathy (dysautonaomia) is a type of SFN. Many dysautonomias are caused by SFN, but they can arise in the central nervous system (e.g. concussion) or the ganglia, which are nerve “relay stations” located right next to the spinal cord. Dr. Chopra listed the same causes as Dr. Chamali, under the SFN lecture, Day 2.
Evaluation: History and physical, skin biopsy QSART, EMG (to rule out large fiber neuropathy)
Treat underlying cause: diabetes, autoimmune disease, high cholesterol. Strict glucose control, including prediabetes, recommended.
Amitriptyline, Nortriptyline-good results (my comment: drying!)
Gabapentin-not very good.
Duloxetine (Cymbalta)- too many of side effects, difficult withdrawal
Milnacipran (Savella)- similar to Cymbalta w/ better side effects (later presenter discouraged SNRIs like these if dysautonomia)
Topical cream (consider Ted’s pain cream) DO NOT use capsaicin, irritates nerves.
3. Low dose naltrexone (LDN)1.5- 4.5 once a day, start at 0.5 mg
4.Treat Mast cell activation syndrome when present. It causes inflamed nerves.
Mast Cell Activation Syndrome (MCAS) refers to over activation of mast cells, a type of immune cell involved in allergic reactions. MCAS often co-occurs with dysautonomia, SFN, and many pain syndromes. The diagnosis is mostly based on clinical presentation, because testing can be difficult and inaccurate. Complex and controversial topic.
Treating MCAS can reduce pain of all types.
Ketotifen (compounded, hard to find) oral cromolyn.
Quercetin (OTC supplement) 500 mg twice a day.
Avoid trigger foods, air quality issue: molds, toxins, fragrances
5. Treat migraines which are very common in dysautonomia.
CGRP inhibitors such as Emgality often very helpful with few side effects.
Sequential compression boots ((Amazon) good for bad POTS/ headache day (must lie down to use)
6. Correct neck balance/ cranial-cervical instability (Chiari, Ehlers Danlos Syndrome) -this can improve POTS.
7. Treat muscle spasms/ pain.
Magnesium helpful. If can’t tolerate oral Mg (rec. chelated by Solgar) try Epson salt bath or topical creams (My comment: warm baths not good idea for POTS)
Small doses levo-dopa (Sinemet) may help
8. Gut dysmotility : diarrhea, constipation, both, nausea, gastroparesis
Multiple medications mentioned He skimmed over treatments quickly, although highlighted Prucalopride (Resolor/ Montegrity) which can be hard to obtain in the US. (Unclear on the indication, but he was very enthusiastic about this drug).
Mentioned low FODMAP diet, but did not go into.
9. Treat central sensitization. Occurs with all chronic pain conditions, but especially neuropathic.
Be sure to have correct Vit. D and Calcium levels.
OTCs - alpha lipoic acid and N-acetyl cysteine (doses not given)
Cannabis helps some. Avoid Hemp sources.
LDN (Low dose naltrexone): improves pain, fatigue, MCAS. Takes a few weeks to see response. (item 3)
10. Misc, treatments: not commonly used, but may help:
Low does ketamine nasal spray (off label, used in treatment resistant depression) May cause nausea, vomiting, diarrhea.
Ketamine IV (last resort)
Near Future: Vagus nerve stim can reduce overall sympathetic activation
11. Restless Leg syndrome
L dopa, ½ pill bedtime(Sinemet 25/ 100)
Exercise Therapy as a Dysautonomia Management Tool, Nicole Mirananda, PT, DPT
Highly Recommend, even if you don’t have dysautonomia
First, as stated by multiple speakers: Deconditioning does not cause POTS or other dysautonomias. However, “being out of shape” makes these worse.
This presentation is phenomenal. It explains why exercise therapy helps dysautonomia, and makes you feel better overall. The trick is to learn how to add in exercise that helps (this takes time to build up) without making your symptoms worse.
A few key points, but the practical aspects of this presentation are really worth watching.
It is important to get some baseline control of symptoms before adding activity through multiple lifestyle measures and medication.
Exercise therapy usually fails due to inadequate support by trained professionals and unrealistic goals. It is a trial and error process, requiring patience and determination.
Support by professionals (PT, OT, others) who understand dysautonomia is very helpful. This is tricky; there are not a lot out there. However, with this talk and resources, many patients can make progress. She provides numerous practical tips and resources.
Realistic goals: May need to start off with as little as 30 seconds of activity. Core exercises are usually a good place to start). The CHOP protocol can be a helpful guide.
Learning intuitively what works in very small/ incremental trials. Need to figure out how to make exercise work for you without worsening symptoms.
Explains how posture corrections often improve fatigue and dizziness. Usually need to work with PT on this.
Expert Q and A: Clair Fancomano MD, Brent Goodman, MD, Lauren Stiles, JD
An interesting and roving discussion. Here are a few things that caught my attention:
Most patients with dysautonomia experience brain fog.
The problem with complex diseases: Need for multidisciplinary teams. This rarely happens. Having a PCP who is interested and willing to learn more can be helpful.
POTS may be an autoimmune disorder, but we still don’t understand the cause.
Concussion often triggers POTS or dysautonomias. Even though people feel “dizzy”, vestibular testing is almost always normal.
Much misc. on EDS (Ehlers Danlos syndrome)
Day 4: October 18, 2020
Autoimmune Autonomic Ganglionopathy (AAG), Steven Vernino, MD, PhD
I found this fascinating, but AAG is a rare cause of dysautonomia. He discussed the difference between AAG, autonomic failure, and POTS. They have many symptoms in common, but different causes. Treatments are similar.
The POTS/ OI Workup: What should we screen for? Brent Goodman, MD
This is an excellent presentation, although much of the content about diagnosis and treatment was covered in earlier presentations. The November 7, 2020 virtual Sjogren’s Foundation conference presentation is more concise and focuses specifically on Sjogren’s and dysautonomia. I highly recommend watching that if you get a chance.
Many unknowns on these topics: mechanisms, genetics, biomarkers, long term natural history. No consensus on approach to evaluation.
Important features of evaluation:
If POTs, subtype
Extent of impairment
Identify comorbidities such as diabetes, AI diseases, vitamin def (esp B 12), Mast cell activation (gave list of tests)
Use these as a platform of treatment (autoimmune vs diabetes vs concussion as cause all call for different approaches)
Diagnostic evaluation may need to be ongoing, repeated for changes in clinical status.
Tests (do not necessarily need all)
Autonomic tests such as Tilt table test, QSART
GI motility testing (not sure exact tests),
Skin biopsy SFN, lip biopsy if Sjogren’s suspected and SSA negative, ECG/ echocardiogram, thyroid, CBC, supine/ standing catecholamines
EDS/ joint mobility tests
Tests for viral infection?? HIV, hepatitis, EBV (not sure if he specified)
Mast cell activation (MCAS) which is often comorbid, anemia, adrenal insufficiency, pheochromocytoma, thyroid disease, PTSD, weight loss esp. due to eating disorders/ and chronic volume depletion.
Gastrointestinal manifestations of dysautonomias:
Swallowing dysfunction/ esophageal dysmotility are VERY COMMON in POTS
Abdominal pain/ bloating may be due to gastroparesis.
In the context of dysautonomia and autoimmune diseases, DO NOT attribute GI symptoms including constipation and diarrhea to “irritable bowel syndrome” which he expresses great skepticism of being an actual entity, but rather another term that people use when they don’t understand symptoms and would rather write it off as a functional disorder.
30 % with POTS test positive MCAS.
POTS/ MCAS/ Sjogren’s/ Migraine combo is common. MCAS–dysautonomia relationship is not fully understood. There are many overlapping features of Dysautonomia/ MCAS.
Blitz review of MCAS symptoms: Hives, itchy skin, flushing face and chest, diarrhea/ bloating, postural hypertensions, bladder pain/ frequency / urgency without UTI (may be a cause of interstitial cystitis)
Recurrent anaphylaxis, ? bone pain ? hair loss
Reviewed tests, which are sometimes normal.
My NOTE: see YOUTUBE presentations by Dr. Ann Maitland for better description MCAS.
Autoimmunity in POTS, Artur Fedorowski, MD
Extremely academic and dense; don’t recommend for patients.
Non-Pharmacological Management of POTS, Tae Chung, MD
Much basic review of hydration/electrolytes/ exercise, lifestyle changes. Repeated the same points as the excellent presentation by Nicole Miranda on day 2. Only addition was he suggested getting an electronic heart rate/ blood pressure monitor.
Pharmacological Management of POTS, Satish Raj, MD
The basics of treatment have been repeated many times in the conference. Not all presenters agree on medical management, especially when it comes to Beta blockers and DDAVP (desmopressin).
POTS is not just tachycardia, patients feel awful when upright. Plasma volume is usually low, typically 15 % lower than it should be when adjusted for body size.
Concepts around POTS medications/ treatments:
Agents that increase blood volume:
Water, salt supplements (many products discussed; Liquid IV is a favorite)
IV saline- 1-2 liters can help a lot but temporary
Acute DDAVP treatment helps, often with remarkable benefit for part of the day. Can cause low sodium levels. Tab or nasal spray. Dr Raj likes to reserve for special events, can help you feel ok for 3-4 hours. Vs. Blair Grubb, 0.2 mg at bedtime with routine sodium levels.
Pyridostigmine (Mestinon)- side effects: diarrhea, salivation (good!),nausea
Beta blocker: Propranolol (low dose, 4 x/ day) Many don’t tolerate due to low stroke volume (amount of blood entering the heart) due to low blood volume. Use low dose to start
He likes propranolol and midodrine as first line. Propranol controversial among specialists.
OTHER comments on POTS treatments:
Anything that includes NE reuptake inhibitors: not good, rev up sympathetic nervous system, may increase heart rate. (Does not like SNRIs) Also controversial; other specialists do use.
SSRIs (Zoloft etc) may help.
Avoid verapamil: dilates blood vessels
Sub Q IG : early data looks good need more studies.
Brain fog: Modafinil used off label in POTS, etc. Helps some, seems to increase resistance to fatigue. Other stimulants discussed, but concern re stimulate sympathetic nervous system.
Expert Q and A, Closing, Vernino, Pace, Stiles
POTS is not just tachycardia. Brain fog is a huge problem. Some patients have orthostatic intolerance that looks like POTS, but do not meet the cutoff of heart rate rising 30 bpm with standing. This POTS cutoff is probably artificial; need for biomarkers to diagnose the condition.
POTS often associated with insomnia, hypersomnia
Why don’t we have a better understanding of POTS and other dysautonomias?
Stigma: Dysautonomias are often labeled as “functional disorders.” Even neurologists who specialize in dysautonomia can be thought of as quacks which is rather disturbing, given that this is a highly specialized academic field.
Massive need for MD education, neurology fellowships in in the autonomic field.
Silo problem: complex disorders can’t be managed in silos. GI specialists and rheumatologists are often not trained re dysautonomia. Sjogren’s researchers are often not talking with autonomic researchers. The overlap is immense.
Many COVID patients are developing POTS. Sadly, the onslaught of new patients is providing an opportunity for more robust research, helping us get a better handle on the probable autoimmune mechanisms behind these conditions.